Form 4: Adam Lenkowsky Executes BMY Stock Vesting Transaction

EVP and Chief Commercial Officer Adam Lenkowsky reported the vesting and tax-related disposition of Bristol Myers Squibb market share units.

Summary

• Adam Lenkowsky, EVP and Chief Commercial Officer, acquired 1,373 shares of common stock upon the vesting of market share units granted on May 1, 2023.
• A downward adjustment of 203 shares was applied due to the performance factor associated with the market share units.
• 599 shares were withheld by the company to satisfy tax obligations at a price of $58.22 per share.
• Following these transactions, the reporting person holds 19,706 shares directly, with additional indirect holdings in a 401(k) plan and via spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• The transaction reflects the standard vesting of long-term incentive compensation, aligning executive interests with shareholder outcomes.

Negatives

• The performance factor adjustment resulted in a reduction of 203 shares from the initial vesting amount.

Risks

• Market share unit payouts are subject to performance factors ranging from 80% to 225%, creating volatility in the final number of shares received by executives.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of individual executive equity transactions.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive equity compensation typical for large-cap pharmaceutical companies, reflecting standard retention and incentive structures.

Comparison to Industry Standards

• The use of performance-based market share units is consistent with compensation practices at peer pharmaceutical firms like Pfizer, Merck, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Future vesting of remaining market share units as per the original grant schedule.

Key Dates

Keywords

Bristol Myers Squibb, BMY, Insider Trading, Form 4, Executive Compensation, Market Share Units